BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol 2012;26:205-10. [PMID: 22506260 DOI: 10.1155/2012/751057] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Kitagawa K, Omoto C, Oda T, Araki A, Saito H, Shigemura K, Katayama T, Hotta H, Shirakawa T. Oral Combination Vaccine, Comprising Bifidobacterium Displaying Hepatitis C Virus Nonstructural Protein 3 and Interferon-α, Induces Strong Cellular Immunity Specific to Nonstructural Protein 3 in Mice. Viral Immunol 2017;30:196-203. [PMID: 28112593 DOI: 10.1089/vim.2016.0111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Rizzetto M, Grotzinger K, Theodore D, Demuth D, Irving WL, Manns M, Roughley A, Forssen UM. Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries. J Viral Hepat 2014;21:e129-34. [PMID: 24698004 DOI: 10.1111/jvh.12256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis. 2014;27:36-45. [PMID: 24305043 DOI: 10.1097/qco.0000000000000034] [Cited by in Crossref: 43] [Cited by in F6Publishing: 13] [Article Influence: 5.4] [Reference Citation Analysis]
4 Gómez ME, Gentile EA, Martini MF, Cuestas ML, Mathet VL, Moltrasio GY, Moglioni AG. Synthesis of New Indanyl Nucleoside Analogues and their Biological Evaluation on Hepatitis C Virus (HCV) Replicon. Molecules 2019;24:E990. [PMID: 30862130 DOI: 10.3390/molecules24050990] [Reference Citation Analysis]
5 Satsangi S, Mehta M, Duseja A, Taneja S, Dhiman RK, Chawla Y. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C. J Gastroenterol Hepatol. 2017;32:859-863. [PMID: 27624314 DOI: 10.1111/jgh.13595] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
6 Kumari S, Sharma S, Advani D, Khosla A, Kumar P, Ambasta RK. Unboxing the molecular modalities of mutagens in cancer. Environ Sci Pollut Res Int 2021. [PMID: 34611806 DOI: 10.1007/s11356-021-16726-w] [Reference Citation Analysis]
7 Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S. Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health 2020;13:773-83. [PMID: 31870632 DOI: 10.1016/j.jiph.2019.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
8 El-Dahshan D, Bahy D, Wahid A, Ahmed AE, Hanora A. Two novel SNPs in the promoter region of PKR gene in hepatitis C patients and their impact on disease outcome and response to treatment. Arab J Gastroenterol 2018;19:106-15. [PMID: 30245117 DOI: 10.1016/j.ajg.2018.06.002] [Reference Citation Analysis]
9 Wang H, Wang S, Cheng L, Chen L, Wang Y, Qing J, Huang S, Wang Y, Lei X, Wu Y, Ma Z, Zhang L, Tang Y. Discovery of Imidazo[1,2-α][1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor. ACS Med Chem Lett 2015;6:977-81. [PMID: 26396683 DOI: 10.1021/acsmedchemlett.5b00159] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
10 Kim D, Goo JI, Kim MI, Lee SJ, Choi M, Than TT, Nguyen PH, Windisch MP, Lee K, Choi Y, Lee C. Suppression of Hepatitis C Virus Genome Replication and Particle Production by a Novel Diacylglycerol Acyltransferases Inhibitor. Molecules 2018;23:E2083. [PMID: 30127285 DOI: 10.3390/molecules23082083] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Jin G, Lee S, Choi M, Son S, Kim GW, Oh JW, Lee C, Lee K. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors. Eur J Med Chem 2014;75:413-25. [PMID: 24561671 DOI: 10.1016/j.ejmech.2014.01.062] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
12 Luna JM, Saeed M, Rice CM. Taming a beast: lessons from the domestication of hepatitis C virus. Curr Opin Virol 2019;35:27-34. [PMID: 30875640 DOI: 10.1016/j.coviro.2019.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Mandal A, Ganta KK, Chaubey B. Combinations of siRNAs against La Autoantigen with NS5B or hVAP-A Have Additive Effect on Inhibition of HCV Replication. Hepat Res Treat 2016;2016:9671031. [PMID: 27446609 DOI: 10.1155/2016/9671031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
14 Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst Pharmacol 2014;3:e88. [PMID: 24384783 DOI: 10.1038/psp.2013.71] [Cited by in Crossref: 119] [Cited by in F6Publishing: 111] [Article Influence: 14.9] [Reference Citation Analysis]
15 Greenberg KI, Perazella MA, Atta MG. HIV and HCV Medications in End-Stage Renal Disease. Semin Dial 2015;28:397-403. [PMID: 25845407 DOI: 10.1111/sdi.12367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Lin HM, Wu PS, Hu HS, Chang WC, Wu RH, Tian JN, Chern JH, Yueh A. Development of robust genotype 1a hepatitis C replicons harboring adaptive mutations for facilitating the antiviral drug discovery and study of virus replication. J Virol Methods 2018;259:10-7. [PMID: 29782889 DOI: 10.1016/j.jviromet.2018.05.010] [Reference Citation Analysis]
17 Tran TN, Nguyen NT. In Silico Screening for Potent Anti-HCV Compounds with Inhibitory Activities Toward the NS3/4A Protease. Int J Pept Res Ther 2019;25:1033-40. [DOI: 10.1007/s10989-018-9750-5] [Reference Citation Analysis]
18 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
19 Lupo F, Russo R, Iolascon A, Ieluzzi D, Siciliano A, Toniutto P, Matté A, Piovesan S, Raffetti E, Turrini F, Dissegna D, Donato F, Alberti A, Zuliani V, Fattovich G, De Franceschi L. Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients. Liver Int 2016;36:49-58. [PMID: 26104535 DOI: 10.1111/liv.12900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
20 C Pak S, Alastal Y, Khan Z, Darr U. Viral Hepatitis in South Korea. Euroasian J Hepatogastroenterol 2017;7:163-5. [PMID: 29201801 DOI: 10.5005/jp-journals-10018-1240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
21 Balasubramanian K, Patil VM. Quantum molecular modeling of hepatitis C virus inhibition through non-structural protein 5B polymerase receptor binding of C5-arylidene rhodanines. Comput Biol Chem 2018;73:147-58. [PMID: 29486389 DOI: 10.1016/j.compbiolchem.2018.01.008] [Reference Citation Analysis]
22 Vita S, Zuccalà P, Savinelli S, Mascia C, Rossi R, Schiavone F, Marocco R, Tieghi T, Iannetta M, Nijhawan P, Zingaropoli MA, d'Ettore G, Vullo V, Mastroianni CM, Lichtner M. Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection. J Immunol Res 2020;2020:2781350. [PMID: 32258171 DOI: 10.1155/2020/2781350] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Barton K, Church D, Onofrey S, Cocoros N, DeMaria A Jr. Follow-up testing for hepatitis C virus infection: an analysis of Massachusetts surveillance data, 2007-2010. Public Health Rep 2014;129:403-7. [PMID: 25177051 DOI: 10.1177/003335491412900503] [Reference Citation Analysis]
24 Knodel MM, Targett-Adams P, Grillo A, Herrmann E, Wittum G. Advanced Hepatitis C Virus Replication PDE Models within a Realistic Intracellular Geometric Environment. Int J Environ Res Public Health 2019;16:E513. [PMID: 30759770 DOI: 10.3390/ijerph16030513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Venkatesan A, Prabhu Dass J F. Review on chemogenomic approaches towards hepatitis C viral targets. J Cell Biochem 2019;120:12167-81. [PMID: 30887580 DOI: 10.1002/jcb.28581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Johnson M, Borland J, Chen S, Savina P, Wynne B, Piscitelli S. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir. Br J Clin Pharmacol 2014;78:1043-9. [PMID: 24838177 DOI: 10.1111/bcp.12428] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
27 Lee S, Yoon KD, Lee M, Cho Y, Choi G, Jang H, Kim B, Jung DH, Oh JG, Kim GW, Oh JW, Jeong YJ, Kwon HJ, Bae SK, Min DH, Windisch MP, Heo TH, Lee C. Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase. Br J Pharmacol 2016;173:191-211. [PMID: 26445091 DOI: 10.1111/bph.13358] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
28 Knodel MM, Nägel A, Reiter S, Vogel A, Targett-Adams P, McLauchlan J, Herrmann E, Wittum G. Quantitative Analysis of Hepatitis C NS5A Viral Protein Dynamics on the ER Surface. Viruses 2018;10:E28. [PMID: 29316722 DOI: 10.3390/v10010028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Chan H, Hassali MA, Md Said R, Abu Hassan MR. Treatment Coverage and Drug Expenditure in Hepatitis C Patients From 2013 to 2019: A Journey of Improving Treatment Accessibility in Malaysia Through Government-led Initiatives. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.107372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Magri A, Reilly R, Scalacci N, Radi M, Hunter M, Ripoll M, Patel AH, Castagnolo D. Rethinking the old antiviral drug moroxydine: Discovery of novel analogues as anti-hepatitis C virus (HCV) agents. Bioorg Med Chem Lett 2015;25:5372-6. [PMID: 26428870 DOI: 10.1016/j.bmcl.2015.09.029] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
31 Palak A, Livoti C, Audibert C. Considerations on bringing warehoused HCV patients into active care following interferon-free, direct-acting antiviral drug approval. Postgrad Med 2017;129:471-5. [PMID: 28277812 DOI: 10.1080/00325481.2017.1304795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
32 Dorababu A. Indole - a promising pharmacophore in recent antiviral drug discovery. RSC Med Chem 2020;11:1335-53. [PMID: 34095843 DOI: 10.1039/d0md00288g] [Cited by in Crossref: 8] [Article Influence: 4.0] [Reference Citation Analysis]
33 Li Y, Wang D, Yang Y, Zhang J, Han C, Wang J, Gao W, Zhang G, Sun X, Wang B, Zhang S, Yang L. The 3D-QSAR and pharmacophore studies of pyrimidine derivatives as HCV replication (replicase) inhibitor. Med Chem Res 2015;24:2033-42. [DOI: 10.1007/s00044-014-1256-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Guaraldi G, Maurice JB, Marzolini C, Monteith K, Milic J, Tsochatzis E, Bhagani S, Morse CG, Price JC, Ingiliz P, Lemoine M, Sebastiani G; SHIVER Network. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. Hepatology 2020;71:1831-44. [PMID: 32052857 DOI: 10.1002/hep.31177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
35 Knodel MM, Reiter S, Targett-Adams P, Grillo A, Herrmann E, Wittum G. 3D Spatially Resolved Models of the Intracellular Dynamics of the Hepatitis C Genome Replication Cycle. Viruses 2017;9:E282. [PMID: 28973992 DOI: 10.3390/v9100282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]